Abstract
Background
Steroid 21-hydroxylase deficiency is an autosomal recessive disorder, present in 90–95% of all cases with congenital adrenal hyperplasia (CAH). The classical simple virilizing (SV) form of the disease causes virilization of the external genitalia in newborn females and pseudo-precocious puberty in both sexes, due to reactive androgen overproduction.
Case presentation
We describe a 3.5-year-old girl presenting with pubarche, P2 according to Tanner, advanced bone age of 6 years and 10 months, and high serum levels of 17-hydroxyprogesterone (17-OHP). Molecular analysis of the nine most common pseudogene-derived CYP21A2 point mutations was performed in the patient and her family members using the polymerase chain reaction/amplification-created restriction site (PCR/ACRS) method. We detected the P30L/I172N genotype in the patient. She had inherited a mild P30L mutation from her mother and a severe I172N mutation from her father.
Conclusions
Although the CAH phenotype is determined by the allele that produces most of the enzyme activity and the mild non-classical (NC) phenotype should be expected, the mild P30L known to be more virilizing probably induced the classical SV phenotype in our patient. A continuous regimen of hydrocortisone at a recommended dose failed to decrease the 17-OHP sufficiently. Careful tapering of the dose did not help, and her pubic hair advanced to P3 according to Tanner. Individually tailored treatment is warranted in this patient.
Acknowledgments
We would like to thank the family of the patient for their cooperation in providing valuable information about their family history and participation in the study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.
Ethical statement: Written informed consent was obtained from the patient for the publication of this case report.
References
1. Bidet M, Bellanne-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009;94:1570–8.10.1210/jc.2008-1582Search in Google Scholar PubMed
2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245–91.10.1210/edrv.21.3.0398Search in Google Scholar PubMed
3. Deneux C, Tardy V, Dib A, Mornet E, Billaud L, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2001;86:207–13.10.1210/jcem.86.1.7131Search in Google Scholar PubMed
4. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57:320–6.10.1210/jcem-57-2-320Search in Google Scholar PubMed
5. Miller WL, Morel Y. The molecular genetics of 21-hydroxylase deficiency. Annu Rev Genet 1989;23:371–93.10.1146/annurev.ge.23.120189.002103Search in Google Scholar PubMed
6. Speiser PW, New MI, White PC. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1. N Engl J Med 1988;319:19–23.10.1056/NEJM198807073190104Search in Google Scholar PubMed
7. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985;37:650–67.10.1097/00006254-198604000-00017Search in Google Scholar PubMed
8. Tanner JM. Growth at adolescence; with a general consideration of the effects of hereditary and environmental factors upon growth and maturation from birth to maturity. Oxford: Blackwell Scientific Publications, 1962.Search in Google Scholar
9. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966;41:613–35.10.1136/adc.41.220.613Search in Google Scholar PubMed PubMed Central
10. Lee HH, Chao HT, Ng HT, Choo KB. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996;33:371–5.10.1136/jmg.33.5.371Search in Google Scholar PubMed PubMed Central
11. Anastasovska V, Kocova M. Genotype-phenotype correlation in CAH patients with severe CYP21A2 point mutations in the Republic of Macedonia. J Pediatr Endocrinol Metab 2010;23:921–6.10.1515/jpem.2010.147Search in Google Scholar PubMed
12. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4205–14.10.1210/jc.2006-1645Search in Google Scholar PubMed
13. Anastasovska V, Milenkovic T, Kocova M. Direct molecular diagnosis of CYP21A2 point mutations in Macedonian and Serbian patients with 21-hydroxylase deficiency. J Med Biochem 2015;34:53–7.Search in Google Scholar
14. Anastasovska V, Kocova M. Molecular analysis of a family with congenital adrenal hyperplasia - genotype/phenotype discrepancy. BJMG 2007;10:23–7.10.2478/v10034-008-0003-3Search in Google Scholar
15. Tusie-Luna MT, Speiser PW, Dumic M, New MI, White PC. A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol Endocrinol 1991;5:685–92.10.1210/mend-5-5-685Search in Google Scholar PubMed
16. Kocova M, Janevska V, Anastasovska V. Testicular adrenal rest tumors in boys with 21-hydroxylase deficiency, timely diagnosis and follow-up. Endocr Connect 2018;7:544–52.10.1530/EC-18-0097Search in Google Scholar PubMed PubMed Central
17. New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA 2013;110:2611–6.10.1073/pnas.1300057110Search in Google Scholar PubMed PubMed Central
18. Amor M, Parker KL, Globerman H, New MI, White PC. Mutation in the CYP21B gene (Ile172Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988;85:1600–4.10.1073/pnas.85.5.1600Search in Google Scholar PubMed PubMed Central
19. Hsu LC, Hsu NC, Guzova JA, Guzov VM, Chang SF, et al. The common I172N mutation causes conformational change of cytochrome P450c21 revealed by systematic mutation, kinetic, and structural studies. J Biol Chem 1996;271:3306–10.10.1074/jbc.271.6.3306Search in Google Scholar PubMed
20. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584–95.10.1172/JCI115897Search in Google Scholar PubMed PubMed Central
21. Ng SM, Stepien K. Glucocorticoid replacement regimens in the treatment of 21-hydroxylase deficiency congenital adrenal hyperplasia. Cochrane Database Syst Rev 2017;1:CD012517.10.1002/14651858.CD012517Search in Google Scholar
22. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133–60.10.1210/jc.2009-2631Search in Google Scholar PubMed PubMed Central
23. Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2009;2009:624823.10.1186/1687-9856-2009-624823Search in Google Scholar PubMed
24. Stikkelbroeck NM, Otten BJ, Pasic A, Jager GJ, Sweep CG, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:5721–8.10.1210/jcem.86.12.8090Search in Google Scholar PubMed
25. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013;98:2645–55.10.1210/jc.2013-1440Search in Google Scholar PubMed PubMed Central
26. Han TS, Walker BR, Arlt W, Ross RJ. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol 2014;10:115–24.10.1038/nrendo.2013.239Search in Google Scholar PubMed
27. Mass Screening C, Japanese Society for Pediatric E, Japanese Society for Mass S, Ishii T, Anzo M, et al. Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision). Clin Pediatr Endocrinol 2015;24:77–105.10.1297/cpe.24.77Search in Google Scholar PubMed PubMed Central
28. Debono M, Price JN, Ross RJ. Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab 2009;23:221–32.10.1016/j.beem.2008.09.010Search in Google Scholar PubMed
29. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110–21.10.1210/jc.2010-0917Search in Google Scholar PubMed PubMed Central
30. Clayton PE, Miller WL, Oberfield SE, Ritzén EM, Sippell WG. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87:4048–53.10.1210/jc.2002-020611Search in Google Scholar PubMed
31. Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2011;76:73–85.10.1159/000327794Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
